Abstract | BACKGROUND AND PURPOSE: METHODS AND MATERIALS:
Axitinib was added to primary cultured endothelial cells, or administered orally to Sv129/BL6 mice bearing radiosensitive MCA/129 sarcoma or radioresistant B16F1 melanoma flank tumors, followed by SDRT. Endothelial apoptosis was assessed by TUNEL assay or bis- benzamide staining. Mice with irradiated tumors were followed for 90days to evaluate the impact of axitinib on SDRT tumor control. RESULTS: Pre-treatment with axitinib increased acute endothelial cell apoptosis following SDRT in vitro, and in vivo for both MCA/129 and B16F1 tumors. Axitinib correspondingly increased SDRT tumor growth delay and complete response rate (by 40%) for both tumors. Administration precisely 1h before SDRT was critical for radiosensitization. CONCLUSIONS:
Axitinib radiosensitizes tumor endothelial cells and enhances tumor cure with SDRT, which may permit dose de-escalation and significantly expand the range of clinical indications for SDRT.
|
Authors | Shyam S Rao, Chris Thompson, Jin Cheng, Adriana Haimovitz-Friedman, Simon N Powell, Zvi Fuks, Richard N Kolesnick |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 111
Issue 1
Pg. 88-93
(Apr 2014)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 24794795
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014. Published by Elsevier Ireland Ltd. |
Chemical References |
- Imidazoles
- Indazoles
- Protein Kinase Inhibitors
- Radiation-Sensitizing Agents
- Axitinib
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Animals
- Apoptosis
(radiation effects)
- Axitinib
- Endothelial Cells
(drug effects)
- Imidazoles
(pharmacology)
- Indazoles
(pharmacology)
- Male
- Melanoma, Experimental
(drug therapy, metabolism, pathology, radiotherapy)
- Mice
- Mice, Inbred C57BL
- Neovascularization, Pathologic
(drug therapy, radiotherapy)
- Protein Kinase Inhibitors
(pharmacology)
- Radiation Tolerance
(drug effects)
- Radiation-Sensitizing Agents
(pharmacology)
- Radiotherapy Dosage
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
- Sarcoma, Experimental
(drug therapy, metabolism, pathology, radiotherapy)
- Signal Transduction
(drug effects)
|